Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVEGYN is a single-dose vaginal ovule fixed-dose combination of **fenticonazole nitrate 600 mg**, **tinidazole 1,000 mg**, and **lidocaine 100 mg** developed by Exeltis for infectious vaginitis. Fenticonazole is an imidazole antifungal that inhibits fungal lanosterol 14-alpha demethylase and thereby disrupts ergosterol synthesis; tinidazole is a nitroimidazole antimicrobial and antiprotozoal agent that produces reactive metabolites causing microbial DNA damage; and lidocaine provides local anesthetic relief by reversibly blocking voltage-gated sodium channels. Clinical studies have evaluated the formulation for bacterial vaginosis, candidal vulvovaginitis, trichomonal vaginitis, and mixed vaginal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EVEGYN.